ORIC-114 is a small molecule commercialized by ORIC Pharmaceuticals, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of ORIC-114’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ORIC-114 is expected to reach an annual total of $110 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
VRN-07 is under development for the treatment of solid tumors including non-small cell lung cancer and HER2 positive breast cancer. The therapeutic candidate is administered through oral route. The drug candidate development is based on voronoi kinase platform technology. The drug candidate act by targeting the epidermal growth factor receptor (EGFR) and HER2 with Exon 20 insertions.
ORIC Pharmaceuticals Overview
ORIC Pharmaceuticals is clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers. The company provides pipeline products such as ORIC-114, ORIC-944, PLK4 and research publications. Its lead drug candidate ORIC-533, is a selective small molecule antagonist of the glucocorticoid receptor (GR), implicated in resistance to various treatment modalities such as chemotherapy, immunotherapy and anti-hormonal therapy across a broad range of cell lines and tumor types. ORIC Pharmaceuticals is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$91.8 million in FY2022, compared to an operating loss of US$78.9 million in FY2021. The net loss of the company was US$89.1 million in FY2022, compared to a net loss of US$78.7 million in FY2021.
For a complete picture of ORIC-114’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.